Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Dart, G. Jerums, G. Nicholson, M. d’Emden, I. Hamilton‐Craig, G. Tallis, J. Best, M. West, D. Sullivan, P. Bracs, D. Black (1997)
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemiaAmerican Journal of Cardiology, 80
H. Langtry, A. Markham (1999)
FluvastatinDrugs, 57
(2000)
Control de la colesterolemia en España, 2000: instrumento para la prevención cardiovascularClin Invest Arteriosclerosis, 12
H.D. Langtry, A. Markham (1999)
Fluvastatin: a review of its use in lipid disordersDrugs, 57
U.M. Henwood, R.C. Heel (1988)
Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemiaDrugs, 36
S. Lewis, F. Sacks, J. Mitchell, C. East, S. Glasser, Sheren Kell, R. Letterer, M. Limacher, L. Moye, J. Rouleau, M. Pfeffer, E. Braunwald (1998)
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.Journal of the American College of Cardiology, 32 1
J. Sheperd, S.M. Cobe, I. Ford (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study GroupN Engl J Med, 333
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
D. Black, R. Bakker-Arkema, T. Heinonen, J. Nawrocki (1998)
D027: Does the presence of either concurrent hypertension or non-insulin-dependent diabetes mellitus affect the efficacy and safety of atorvastatin in patients with hyperlipidemia?American Journal of Hypertension, 11
A. Oberman, R.A. Kreisberg, Y. Henkin (1992)
Principles and management of lipid disorders
J. Cleeman (1989)
The National Cholesterol Education Program.Clinics in laboratory medicine, 9 1
A. Olsson, M. Eriksson, Owe Johnson, T. Kjellström, J. Lanke, M. Larsen, T. Pedersen, M. Tikkanen, O. Wiklund (2003)
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.Clinical therapeutics, 25 1
Michael Prisant, M. Downton, L. Watkins, H. Schnaper, R. Bradford, A. Chremos, A. Langendorfer (1996)
Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia.The American journal of cardiology, 78 4
A. Olsson, J. Mcmurray, G. Thorgeirsson, C. Spaulding, J. Slattery, K. Pyörälä, O. Faergeman, R. Wright, Kåre Berg, L. Wilhelmsen, T. Pedersen, T. Miettinen, H. White, J. Kjekshus, M. Gnant (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atherosclerosis. Supplements, 5 3
Donald Black, R. Bakker-Arkema, J. Nawrocki (1998)
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.Archives of internal medicine, 158 6
J. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro, P. Beere, A. Langendorfer, E. Stein, W. Kruyer, A. Gotto (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA, 279 20
A. Jula, J. Marniemi, R. Huupponen, A. Virtanen, M. Rastas, T. Rönnemaa (2002)
Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.JAMA, 287 5
Peter Jones, S. Kafonek, I. Laurora, D. Hunninghake (1998)
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)The American journal of cardiology, 81 5
M. Frick, Olli Elo, K. Haapa, O. Heinonen, P. Heinsalmi, Pekka Helo, J. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, H. Mäenpää, M. Mälkönen, M. Mänttäri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom, E. Nikkilä (1987)
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.The New England journal of medicine, 317 20
H. Malhotra, K. Goa (2012)
AtorvastatinDrugs, 61
A. Branchi, A. Fiorenza, A. Rovellini, A. Torri, F. Muzio, S. Macor, D. Sommariva (1999)
Lowering effects of four different statins on serum triglyceride levelEuropean Journal of Clinical Pharmacology, 55
B. Jacotot, R. Benghozi, P. Pfister, David Holmes (1995)
Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.The American journal of cardiology, 76 2
D. Illingworth, E. Stein, Y. Mitchel, C. Dujovne, P. Frost, R. Knopp, P. Tun, R. Zupkis, R. Greguski (1994)
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.Archives of internal medicine, 154 14
H.S. Malhotra, K.L. Goa (2001)
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemiaDrugs, 61
P. Jones, S. Kafonek, I. Laurora (1998)
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [publisher erratum appears in Am J Cardiol 1998 Jul 1; 82 (1): 128]Am J Cardiol, 81
D.G. Smith (2001)
The cost-effectiveness of statins: evidence from the ACCESS trial [abstract no. PVC37]Value Health, 4
J.H. Zavoral, B.J. Haggerty, A.G. Winick (1995)
Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: FLUENT Study Group: Fluvastatin Long-Term Extension TrialAm J Cardiol, 76
J. Downs, M. Clearfield, S. Weis (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPSJAMA, 279
(1997)
Efficacy of atorvastatin in primary hypercholesterolemiaAm J Cardiol, 79
L. Ose, M. Davidson, W. Insull, Mei Wu, A. Tate, M. Melino, M. Mercuri, Y. Mitchel, E. Stein, J. Kastelein, R. Scott, D. Hunninghake, S. Campodónico, I. Escobar, M. Stepanavage, H. Schrott (2000)
Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with HypercholesterolemiaClinical Cardiology, 23
(1993)
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemiaAm J Cardiol, 71
D. Wood, G. Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä (1998)
Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.European heart journal, 19 10
J. Rindone, D. Hiller, Greg Arriola (1998)
A Comparison of Fluvastatin 40 mg Every Other Day versus 20 mg Every Day in Patients with HypercholesterolemiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 18
(1994)
Randomized trial of cholesterol lowering in 4444 individuals with coronary heart disease: the Scandinavian Simvastatin Survival StudyLancet, 344
Dean Smith (2001)
THE COST‐EFFECTIVENESS OF STATINS: EVIDENCE FROM THE ACCESS TRIALValue in Health, 4
M. Davidson (1994)
Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety.The American journal of medicine, 96 6A
Michael Davidson, J. Mckenney, E. Stein, H. Schrott, R. Bakker-Arkema, R. Fayyad, D. Black (1997)
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.The American journal of cardiology, 79 11
T. Pedersen, A. Olsson, O. Faergeman, J. Kjekshus, H. Wedel, Kåre Berg, L. Wilhelmsen, T. Haghfelt, G. Thorgeirsson, K. Pyörälä, T. Miettinen, B. Christophersen, J. Tobert, T. Musliner, T. Cook (1998)
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)Circulation, 97 15
J.D. Banga, B. Jacotot, P. Pfister (1994)
Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study: French-Dutch Fluvastatin Study GroupAm J Med, 96
D. Wood, G. Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä (1998)
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.Atherosclerosis, 140 2
D. Hilleman, J. Phillips, S. Mohiuddin, K. Ryschon, C. Pedersen (1999)
A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.Clinical therapeutics, 21 3
J. Tuomilehto, G. Vidgrén, L. Toivanen, E. Tuomilehto-Wolf, K. Kohtamäki, J. Stengård, P. Zimmet, I. Mackay, M. Rowley, P. Koskela (1994)
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of diseaseThe Lancet, 343
R. Bradford, C. Shear, A. Chremos, C. Dujovne, M. Downton, F. Franklin, A. Gould, M. Hesney, J. Higgins, D. Hurley (1991)
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.Archives of internal medicine, 151 1
(1993)
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemiaAm J Cardiol, 71
D. Wood (1994)
What I doThe American Journal of Medicine, 96
M. Haria, D. McTavish (1997)
Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart diseaseDrugs, 53
R. Bakker-Arkema, J. Best, R. Fayyad, T. Heinonen, A. Marais, J. Nawrocki, D. Black (1997)
A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.Atherosclerosis, 131 1
Heiner Greten, Frank Beil, Jürgen Schneider, Peter Weisweiler, Victor Armstrong, Christiane Keller, Hans-Ulrich Klör, E. Hodenberg, Gottfried Weidinger, Herber Eskötter, Lothar Färber, Gerd Assman (1994)
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.The American journal of medicine, 96 6A
J. Henwood, R. Heel (2012)
LovastatinDrugs, 36
T. Peters, E. Muratti, M. Mehra (1994)
Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.The American journal of medicine, 96 6A
Conrad Blum (1994)
Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.The American journal of cardiology, 73 14
M. Haria, D. McTavish (2012)
PravastatinDrugs, 53
T.K. Peters (1996)
Treatment of dyslipidaemias with fluvastatinBr J Clin Pract Suppl, 77A
L. Ose, M.H. Davidson, E.A. Stein (2000)
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia: World Wide Expanded Dose Simvastatin Study GroupClin Cardiol, 23
B. Jacotot, J. Banga, R. Waite, T. Peters (1995)
Long-term efficacy with fluvastatinas monotherapy and combined with cholestyramine (A 156-week multicenter study)American Journal of Cardiology, 76
T. Heinonen, E. Stein, S. Weiss, J. Mckenney, M. Davidson, L. Shurzinske, D. Black (1996)
The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study.Clinical therapeutics, 18 5
W. Brown, H. Bays, D. Hassman, J. Mckenney, R. Chitra, H. Hutchinson, Elinor Miller (2002)
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.American heart journal, 144 6
D. Karalis, A. Ross, Ralph Vacari, H. Zarren, R. Scott (2002)
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.The American journal of cardiology, 89 6
Jan Banga, B. Jacotot, Pascal Pfister, M. Mehra (1994)
Long-term treatment of hypercholesterolemia with fluvastatin: A 52-week multicenter safety and efficacy studyThe American Journal of Medicine, 96
T. Peters (1995)
Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.The American journal of cardiology, 76 2
R. Renfrew (1984)
Lipid Research Clinics Program.JAMA, 252 18
J. Farmer, L. Washington, Peter Jones, D. Shapiro, A. Gotto, G. Mantell (1992)
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.Clinical therapeutics, 14 5
Gdh MacLaine, H. Patel (2001)
A COST‐EFFECTIVENESS MODEL OF ALTERNATIVE STATINS TO ACHIEVE TARGET LDL‐CHOLESTEROL LEVELSInternational Journal of Clinical Practice, 55
P. Gohlke, T. Unger (1995)
Chronic low-dose treatment with perindopril improves cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin.The American journal of cardiology, 76 15
D. Hilleman, Susan Heineman, P. Foral (2000)
Pharmacoeconomic Assessment of HMG‐CoA Reductase Inhibitor Therapy: An Analysis Based on the CURVES StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 20
J. Nawrocki, S. Weiss, M. Davidson, D. Sprecher, S. Schwartz, P. Lupien, P. Jones, H. Haber, D. Black (1995)
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.Arteriosclerosis, thrombosis, and vascular biology, 15 5
A. Keech, R. Collins, S. MacMahon, J. Armitage, A. Lawson, K. Wallendszus, M. Fatemian, E. Kearney, V. Lyon, J. Mindell (1994)
Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.European heart journal, 15 2
B. Jacotot, J.D. Banga, R. Waite (1995)
Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study): French-Dutch Fluvastatin Study GroupAm J Cardiol, 76
M.J. Koren, D.G. Smith, D.B. Hunninghake (1998)
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolemic patients: a comparison of atorvastatin, simvastatin, lovastatin and fluvastatinPharmacoeconomics, 14
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T. Cole, L. Brown, J. Warnica, J. Arnold, C. Wun, B. Davis, E. Braunwald (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.The New England journal of medicine, 335 14
L. Ferder, M. Bertolami, S. Giannini, J. Cortázar, A. Obonarellano, E. Agner, A. Leth, S. Mattila, M. Tikkanen, J. Fruchart, W. Dutz, K. Gunther, A. Gutschker, G. Heineman, K. Moricke, W. Reuter, E. Steinhagenthiessen, M. Krankenhaus, P. Toutouzas, Y. Tai, A. Rubenstein, J. Rull, L. Ose, F. Garmendia, M. Carrageta, J. Martinscorreia, L. Alvarezsala, J. Gimilio, M. Melino, Y. Mitchel, J. Ng, E. Stein (1993)
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group.The American journal of cardiology, 71 10
J. Herd, J. Herd, J. Herd, C. Ballantyne, C. Ballantyne, C. Ballantyne, J. Farmer, J. Farmer, J. Farmer, J. Ferguson, James Ferguson, James Ferguson, Peter Jones, Peter Jones, Peter Jones, M. West, M. West, M. West, K. Gould, K. Gould, K. Gould, A. Gotto, A. Gotto, A. Gotto (1997)
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).The American journal of cardiology, 80 3
J. Shepherd, S. Cobbe, I. Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop, C. Packard (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaThe New England Journal of Medicine, 333
T. Andrews, C. Ballantyne, J. Hsia, Jeffrey Kramer (2001)
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.The American journal of medicine, 111 3
P. Barter, R. O’Brien (2000)
Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice.Atherosclerosis, 149 1
G. Castańo, R. Menéndez, R. Más, A. Amor, F. Jl, González Rl, Magnolia Lezcay, E. Alvarez (2002)
Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.International journal of clinical pharmacology research, 22 3-4
(1984)
The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart diseaseJAMA, 261
(2001)
Executive summary of the third report of the expert committee on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)JAMA, 285
P. Rubió (2003)
Impacto sobre el Sistema Sanitario Catalán de la aplicación de las recomendaciones del segundo y tercer informes del National Cholesterol Education Program (ATP-II y ATP-III) sobre prevención y control de la hipercolesterolemia en adultosClínica e Investigación en Arteriosclerosis, 15
P. Serruys, D. Foley, G. Jackson, H. Bonnier, C. Macaya, M. Vrolix, A. Branzi, J. Shepherd, H. Suryapranata, P. Feyter, R. Melkert, G. Es, P. Pfister (1999)
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.European heart journal, 20 1
T. Jacobson (1996)
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.The American journal of cardiology, 78 6A
J. Zavoral, B. Haggerty, A. Winick, S. Bergmann (1995)
Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coeezyme a reduefase inhibitorAmerican Journal of Cardiology, 76
Illingworth Dr, Tobert Ja (1994)
A review of clinical trials comparing HMG-CoA reductase inhibitors.Clinical Therapeutics, 16
J. Daubresse (1993)
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.The American journal of cardiology, 71 16
J. Coombs, L. Cornish, P. Hiller, Dean Smith (2001)
PCV36: EVALUATION OF COMPLIANCE AND PERSISTENCE WITH HMG-COA REDUCTASE INHIBITORS AFTER A MYOCARDIAL INFARCTION USING PHARMACY CLAIMS DATAValue in Health, 4
Peters Tk (1994)
Treatment of dyslipidaemias with fluvastatin.The British journal of clinical practice
M. Gold (2016)
Cost-effectiveness in health and medicine
colestyramine in the reduction of low-density lipoprotein-cholesterol (LDL-C) levels and the cost per patient to achieve the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) therapeutic objectives in Spain. Method: The following treatments were evaluated: atorvastatin, simvastatin, and pravastatin 10–40 mg/day; lovastatin and fluvastatin 20–80 mg/day; and colestyramine 12–24 g/day. The cost effectiveness of these treatments was evaluated, in terms of cost per percentage of LDL-C reduction, by comparing annual treatment costs versus the efficacy of LDL-C reduction. Treatment costs included medication costs (2003 wholesale prices), control measures, and the treatment of adverse affects. The efficacy of HMG-CoA reductase inhibitors (statins) was obtained from a meta-analysis of results obtained from clinical trials published between 1993 and 2003 that met the following criteria: monotherapy; >16 weeks of treatment; randomized allocation of individuals to the intervention and comparator groups; dietary treatment for ≥3 months before administration of medication; and double-blind measurement of outcomes. Average and incremental cost-effectiveness ratios were calculated to assess the efficiency of cholesterol-lowering treatments. Results: Efficacy, in terms of percentage of LDL-C reduction, ranged from 10% for colestyramine 12 g/day to 49% for atorvastatin 40 mg/day. Total annual treatment costs ranged from €321 for fluvastatin
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.